Celltrion, Incorporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Celltrion, Incorporation with three other
pharmaceutical manufacturers in Asia:
sales of 30.90 billion Indian Rupees [US$453.58 million]
of which 73%
Yifan Pharmaceutical Co Ltd
(2.43 billion Chinese Renmimbi [US$352.83 million]
of which 68%
was Health Products - Medicine), and
China Animal Husbandry Ind.
based in China
(4.23 billion Chinese Renmimbi [US$613.37 million]
of which 100%
Celltrion, Incorporation reported sales of 603.41 billion Korean Won (US$509.88 million)
December of 2015.
increase of 28.1%
versus 2014, when the company's sales were 471.05 billion Korean Won.
Sales of Bio Business Division saw an increase
30.7% in 2015, from
404.62 billion Korean Won to 528.78 billion Korean Won.
Not all segments of Celltrion, Incorporation experienced an increase in sales in 2015:
sales of Other fell 17.0% to 8.25 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).